INSP Stock Recent News
INSP LATEST HEADLINES
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inspire (INSP) To Contact Him Directly To Discuss Their Options If you purchased or acquired Inspire stock and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE: INSP).
NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP).
Inspire Medical Systems, Inc. (NYSE:INSP ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 11:00 AM EDT Company Participants Carlton Weatherby - Chief Strategy and Growth Officer Ezgi Yagci - Vice President of Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Good morning.
NEW YORK , Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE: INSP).
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE: INSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Inspire Medical Systems faced a major setback after delays in the Inspire V launch, leading to slashed guidance and a sharp share price drop. Despite near-term volatility and margin pressure, the company's valuation now appears attractive at less than 3x sales, supported by a strong balance sheet. Management expects revenue growth to reaccelerate in 2026, offering comfort to long-term investors despite current uncertainty around margins.
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE: INSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.